Immunophenotypic Variations in Mantle Cell Lymphoma

被引：57

作者：

Gao, Juehua ^{[1
]}

Peterson, LoAnn ^{[1
]}

Nelson, Beverly ^{[1
]}

Goolsby, Charles ^{[1
]}

Chen, Yi-Hua ^{[1
]}

机构：

[1] Northwestern Univ, Feinberg Sch Med, Dept Pathol, Chicago, IL 60611 USA

来源：

AMERICAN JOURNAL OF CLINICAL PATHOLOGY | 2009年 / 132卷 / 05期

关键词：

Mantle cell lymphoma; Immunophenotype; Flow cytometry; Ki-67; ABERRANT EXPRESSION; FEATURES; CD23; MCL; ENTITY; GENES; CD5;

D O I：

10.1309/AJCPV8LN5ENMZOVY

中图分类号：

R36 [病理学];

学科分类号：

100103 [病原生物学];

摘要：

Mantle cell lymphoma (MCL) expresses pan-B-cell antigens and is usually CD5+/CD10-/CD23-/FMC7+. In this study, we evaluated 52 patients with confirmed diagnoses of MCL and identified variant immunophenotypes in 21 patients (19148 classical and 214 variant MCLs), including CD5- in 6 (12%) of 52, CD10+ in 4 (8%) of 50, CD23+ in 10 (21%) of 48, and FMC7- in 4 (11%) of 3 7 cases. Three cases showed variations in 2 antigens, including CD5-/CD23+, CD10+/FMC7-, and CD23+/FMC7-; they were all classical MCLs. One blastoid variant MCL was CD23+, and one was FMC7-. Evaluation for proliferation index by immunohistochemical analysis for Ki-67 demonstrated no significant difference between MCLs with variant immunophenotypes and MCLs with typical immunophenotypes. The high proliferation index (>60%) was exclusively seen in the blastoid and pleomorphic variants. Our results indicate that immunophenotypic variations are common in MCL, and recognizing the variability is important for accurate subclassification of B-cell lymphoma.

引用

页码：699 / 706

页数：8

共 27 条

[1]

Clinical utility of CD23 and FMC7 antigen coexistent expression in B-cell lymphoproliferative disorder subclassification [J].

Ahmad, E ;

Garcia, D ;

Davis, BH .

CYTOMETRY, 2002, 50 (01) :1-7

[2]

[Anonymous], 2008, WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues

[3]

Bosch F, 1998, CANCER, V82, P567, DOI 10.1002/(SICI)1097-0142(19980201)82:3<567::AID-CNCR20>3.0.CO

[4]

2-Z

[5]

Molecular heterogeneity in MCL defined by the use of specific VH genes and the frequency of somatic mutations [J].

Camacho, FI ;

Algara, P ;

Rodríguez, A ;

Ruíz-Ballesteros, E ;

Mollejo, M ;

Martínez, N ;

Martínez-Climent, JA ;

González, M ;

Mateo, M ;

Caleo, A ;

Sánchez-Beato, M ;

Menárguez, J ;

García-Conde, J ;

Solé, F ;

Campo, E ;

Piris, MA .

BLOOD, 2003, 101 (10) :4042-4046

[6]

Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade lymphoma Study Group [J].

Determann, Olaf ;

Hoster, Eva ;

Ott, German ;

Bernd, Heinz Wolfram ;

Loddenkemper, Christoph ;

Hansmann, Martin Leo ;

Barth, Thomas E. F. ;

Unterhalt, Michael ;

Hiddemann, Wolfgang ;

Dreyling, Martin ;

Klapper, Wolfram .

BLOOD, 2008, 111 (04) :2385-2387

[7]

Chromosome anomalies detected by interphase fluorescence in situ hybridization:: correlation with significant biological features of B-cell chronic lymphocytic leukaemia [J].

Dewald, GW ;

Brockman, SR ;

Paternoster, SF ;

Bone, ND ;

O'Fallon, JR ;

Allmer, C ;

James, CD ;

Jelinek, DF ;

Tschumper, RC ;

Hanson, CA ;

Pruthi, RK ;

Witzig, TE ;

Call, TG ;

Kay, NE .

BRITISH JOURNAL OF HAEMATOLOGY, 2003, 121 (02) :287-295

[8]

B-cell lymphomas with coexpression of CD5 and CD10 [J].

Dong, HY ;

Gorczyca, W ;

Liu, Z ;

Tsang, P ;

Wu, CD ;

Cohen, P ;

Weisberger, J .

AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2003, 119 (02) :218-230

[9]

Garcia DP, 2001, AM J CLIN PATHOL, V115, P258

[10]

Gong JZ, 2001, AM J CLIN PATHOL, V116, P893

← 1 2 3 →